Detection of minimal residual disease in multiple myeloma
10.3760/cma.j.issn.1009-9921.2018.04.002
- VernacularTitle: 多发性骨髓瘤的微小残留病检测
- Author:
Meijia SI
1
;
Wenming CHEN
Author Information
1. Department of Hematology, Beijing Chao-Yang Hospital Affiliated of Capital Medical University, Beijing 100020, China
- Publication Type:Review
- Keywords:
Multiple myeloma;
Minimal residual disease;
Treatment strategy
- From:
Journal of Leukemia & Lymphoma
2018;27(4):198-200
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a kind of hematological malignant tumors characterized by the unnormal proliferation of plasma cell in the bone marrow, which often occurs in elderly patients and has an obvious increase of incidence. The treatment of MM has made a great progress in the 21st century. Furthermore, with the addition of effective therapies and wide application of remissive treatment combination, the therapeutic goal of MM needs to be reevaluated. Minimal residual disease (MRD) negative status has become increasingly important, and some even consider it as the primary endpoint for therapy.
